What is the share price of Novelix Pharmaceuticals Ltd (NOVELIX) today?
The share price of NOVELIX as on 23rd June 2026 is ₹80.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Novelix Pharmaceuticals Ltd (NOVELIX) share?
The past returns of Novelix Pharmaceuticals Ltd (NOVELIX) share are- Past 1 week: -9.43%
- Past 1 month: 39.67%
- Past 3 months: 48.25%
- Past 6 months: 33.80%
- Past 1 year: 171.43%
- Past 3 years: 736.24%
- Past 5 years: 781.62%
What are the peers or stocks similar to Novelix Pharmaceuticals Ltd (NOVELIX)?
The peers or stocks similar to Novelix Pharmaceuticals Ltd (NOVELIX) include:What is the market cap of Novelix Pharmaceuticals Ltd (NOVELIX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Novelix Pharmaceuticals Ltd (NOVELIX) is ₹190.23 Cr as of 23rd June 2026.What is the 52 week high and low of Novelix Pharmaceuticals Ltd (NOVELIX) share?
The 52-week high of Novelix Pharmaceuticals Ltd (NOVELIX) is ₹92 and the 52-week low is ₹29.33.What is the PE and PB ratio of Novelix Pharmaceuticals Ltd (NOVELIX) stock?
The P/E (price-to-earnings) ratio of Novelix Pharmaceuticals Ltd (NOVELIX) is 74.31. The P/B (price-to-book) ratio is 10.85.Which sector does Novelix Pharmaceuticals Ltd (NOVELIX) belong to?
Novelix Pharmaceuticals Ltd (NOVELIX) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Novelix Pharmaceuticals Ltd (NOVELIX) shares?
You can directly buy Novelix Pharmaceuticals Ltd (NOVELIX) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Novelix Pharmaceuticals Ltd
NOVELIX Share Price
BSE₹80.501.12% (+0.89)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NOVELIX Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NOVELIX Performance & Key Metrics
NOVELIX Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 74.89 | 10.85 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 41.59 | 6.21 | 0.55% |
NOVELIX Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NOVELIX Company Profile
Novelix Pharmaceuticals Ltd engages in trading pharmaceuticals and related products, alongside investments in shares and securities.
SUNPHARMA
PE Ratio
38.94
38.94
1Y Return
12.05%
12.05%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.73
69.73
1Y Return
40.80%
40.80%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.48
29.48
1Y Return
5.56%
5.56%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
21.48
21.48
1Y Return
14.01%
14.01%
Buy Reco %
53.57
53.57
DRREDDY
PE Ratio
25.61
25.61
1Y Return
2.06%
2.06%
Buy Reco %
51.52
51.52
NOVELIX Forecast
NOVELIX Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NOVELIX
NOVELIX
Income
Balance Sheet
Cash Flow
Quarterly Normal View
NOVELIX Income Statement
NOVELIX Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.58 | 0.97 | 0.70 | 3.87 | 5.30 | 20.86 | 22.35 | 36.39 | 48.40 | 25.19 | ||||||||||
Operating & Other expenses | 0.61 | 0.69 | 1.04 | 3.74 | 5.17 | 20.63 | 22.17 | 35.66 | 47.09 | 23.91 | ||||||||||
EBITDA | -0.03 | 0.28 | -0.34 | 0.13 | 0.13 | 0.23 | 0.18 | 0.73 | 1.31 | 1.28 | ||||||||||
| Depreciation/Amortization | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.03 | 0.05 | ||||||||||
| PBIT | -0.04 | 0.27 | -0.34 | 0.13 | 0.13 | 0.21 | 0.17 | 0.72 | 1.28 | 1.23 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBT | -0.04 | 0.27 | -0.34 | 0.13 | 0.13 | 0.21 | 0.17 | 0.72 | 1.28 | 1.23 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.01 | 0.00 | -0.02 | 0.03 | 0.07 | 0.19 | 0.28 | 0.32 | ||||||||||
| Net Income | -0.04 | 0.27 | -0.35 | 0.13 | 0.15 | 0.18 | 0.10 | 0.53 | 1.00 | 0.91 | ||||||||||
| EPS | -0.04 | 0.34 | -0.43 | 0.16 | 0.15 | 0.18 | 0.09 | 0.37 | 0.58 | 0.43 |
NOVELIX Company Updates
NOVELIX Stock Peers
NOVELIX Past Performance & Peer Comparison
NOVELIX Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Novelix Pharmaceuticals Ltd | 74.31 | 10.85 | — |
| Sun Pharmaceutical Industries Ltd | 38.94 | 6.17 | 0.86% |
| Torrent Pharmaceuticals Ltd | 69.73 | 8.58 | 0.85% |
| Cipla Ltd | 29.48 | 3.31 | 0.92% |
NOVELIX Stock Price Comparison
Compare NOVELIX with any stock or ETFCompare NOVELIX with any stock or ETF
NOVELIX
NOVELIX Holdings
NOVELIX Shareholdings
NOVELIX Promoter Holdings Trend
NOVELIX Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.41%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
NOVELIX Institutional Holdings Trend
NOVELIX Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NOVELIX Shareholding Pattern
NOVELIX Shareholding Pattern
NOVELIX Shareholding History
NOVELIX Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing NOVELIX stock
smallcases containing NOVELIX stock
Looks like this stock is not in any smallcase yet.
NOVELIX Events
NOVELIX Events
NOVELIX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NOVELIX has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NOVELIX Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NOVELIX has not given any dividends in last 5 years
NOVELIX Upcoming Dividends
NOVELIX Upcoming Dividends
No upcoming dividends are available
NOVELIX Past Dividends
NOVELIX Past Dividends
Cash Dividend
Ex DateEx DateAug 16, 2012
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Aug 16, 2012
Cash Dividend
Ex DateEx DateSep 22, 2011
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2011
NOVELIX Stock News & Opinions
NOVELIX Stock News & Opinions
Articles & Videos
Corporate
Corporate
Novelix Pharmaceuticals EGM scheduledNovelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 1 July 2026.
2 weeks agoCapital Market - Live
Spotlight
Spotlight
Novelix Pharma inks pact with German Firm to boost Astaxanthin outputAstaxanthin is a potent, naturally occurring carotenoid antioxidant. It is primarily used as a dietary supplement to combat oxidative stress, reduce inflammation, and support healthy skin, eyes, and cardiovascular function The company clarified that GMBU e.V. and its affiliates are not related to the promoter, promoter group, or group companies of Novelix Pharmaceuticals. The transaction does not fall under related-party transactions, and no promoter or promoter group entity has any interest in the agreement. Novelix Pharmaceuticals is engaged in business of trading of pharmaceuticals and related products and is into the business of trading of shares and securities. The companys; consolidated net profit surged 405.56% to Rs 0.91 crore on 20.76% jump in revenue from operations to Rs 25.19 crore in Q4 FY26 over Q4 FY25. The counter rallied 3.28% to end at Rs 54.40 n the BSE.Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Earnings
Earnings
Novelix Pharmaceuticals standalone net profit rises 405.56% in the March 2026 quarterNet profit of Novelix Pharmaceuticals rose 405.56% to Rs 0.91 crore in the quarter ended March 2026 as against Rs 0.18 crore during the previous quarter ended March 2025. Sales rose 20.76% to Rs 25.19 crore in the quarter ended March 2026 as against Rs 20.86 crore during the previous quarter ended March 2025. For the full year,net profit rose 3100.00% to Rs 2.56 crore in the year ended March 2026 as against Rs 0.08 crore during the previous year ended March 2025. Sales rose 330.70% to Rs 132.31 crore in the year ended March 2026 as against Rs 30.72 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales25.1920.86 21 132.3130.72 331 OPM %5.081.10 -2.630.46 - PBDT1.280.23 457 3.510.16 2094 PBT1.230.21 486 3.410.12 2742 NP0.910.18 406 2.560.08 3100 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Corporate
Novelix Pharmaceuticals to announce Quarterly ResultNovelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2026.
3 weeks agoCapital Market - Live
Earnings
Earnings
Novelix Pharmaceuticals standalone net profit rises 566.67% in the December 2025 quarterNet profit of Novelix Pharmaceuticals rose 566.67% to Rs 1.00 crore in the quarter ended December 2025 as against Rs 0.15 crore during the previous quarter ended December 2024. Sales rose 813.21% to Rs 48.40 crore in the quarter ended December 2025 as against Rs 5.30 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales48.405.30 813 OPM %2.712.45 - PBDT1.310.13 908 PBT1.280.13 885 NP1.000.15 567 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Novelix Pharmaceuticals board approves allotment of 23.20 lakh equity sharesThe board of Novelix Pharmaceuticals at its meeting held on 12 February 2026 has approved allotment of 23,20,000 equity shares of Rs 10 each at an issue price of Rs 60 per equity share (including a premium of Rs 50 per equity share) by way of preferential issue through private placement. Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Novelix Pharmaceuticals to conduct board meetingNovelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Corporate
Novelix Pharmaceuticals EGM scheduledNovelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 January 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Novelix Pharmaceuticals EGM scheduledNovelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 January 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
Novelix Pharmaceuticals to convene board meetingNovelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 December 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 82.95%, vs industry avg of 10.37%
Over the last 5 years, market share increased from 0% to 0.01%
Over the last 5 years, net income has grown at a yearly rate of 0%, vs industry avg of 19.71%